drugset / Trial / NCT02456103
Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label extension study for participants who completed a Phase 3, placebo-controlled study of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.
Timeline
- Start
- 2015-08-31
- Primary completion
- 2017-06-02
- Completion
- 2017-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ataluren | Small molecule | 10 mg/kg | Oral |
| Subject | Ataluren | Small molecule | 20 mg/kg | Oral |